Lynchburg Journal of Medical Science

Lynchburg Journal of Medical Science


Critical Care


Thomas Colletti, DHSc, PA-C, DFAAPA


The novel coronavirus, SARS-CoV-2, is responsible for the range of clinical diseases now known as COVID-19. While most cases of COVID-19 are either asymptomatic or consist of mild to moderate disease, a subset of the population develops severe or critical illness. Based on the clinical scenario, there are a variety of pharmacologic and nonpharmacologic therapeutic options. This article reviews recommendations for implementing these therapeutic options in severe or critically ill patients with COVID-19.


Available when accessing via a campus IP address or logged in with a University of Lynchburg email address.

Off-campus users can also use 'Off-campus Download' button above for access.